Repros Therapeutics Inc. (RPRX) announced after the bell Wednesday that Androxal met both co-primary endpoints in its first pivotal study.
Repros Therapeutics has gapped open sharply higher Thursday and is now up 6.57 at $15.70 on above average volume. The stock has risen to a 2-month high and has re-crossed both its 50 and 200-day moving averages.
For comments and feedback: editorial@rttnews.com